Терапевтична ефективність комплексу амінокислот у хворих за епілепсії собак
Abstract
THERAPEUTIC EFFICACY OF AMINO ACID
COMPOSITION IN EPILEPTIC DOGS
M. I. Tsvilikhovskiy, O.M. Yakymchuk, N. Y. Ivanchenko
Abstract. The epilepsy is the most widespread chronic neurological disorders among animals, as well as among people. Nevertheless the efficacy and safety of the major part of antiepileptic drugs is not satisfactory. For this reason investigations aimed for elaborating new drugs are still actual. According to scientific literature such amino acids, as leucine, isoleucine, valine, glycine and taurine appears to be promising regarding antiepileptic effect. Result regarding the efficacy of the oral simultaneously administration of mentioned amino acids to epileptic dogs («unknown cause epilepsy» in correspondence to IVETF) are represented in this publication. The experimental group was formed with eight epileptic dogs which during two-mounth period were given amino acids in such daily doses per kilogram divided equally in order to be given every 8 h: L-leucine – 150 mg, L-isoleucine – 275 mg; L- valine – 240 mg; glycine – 300 mg; taurine – 240 mg. The efficacy was estimated by visual detection of paroxysmal activity and quantitative electroencephalography (QEEG) using fast Fourier transformation (FFT) and by monitoring seizure frequency. Clinically antiepileptic effect of amino acid composition was represented by the prolongation of interictal periods per 2 to 3 times in 37,5 % of dogs and by elimination of cluster seizures.
References
Grill, V., Bjjorkhem, M., Gutniak, M., Lindqvisk M. (1992). Brain uptake and release of amino acids in non diabetic and insulin-dependent diabetic subjects: important role of glutamine release for nitrogen balance. Metabolism, № 42, 28–32.
Chandler K. (2006). Canine epilepsy: what can we learn from human seizure disorders? Vet J., № 172, 207–217.
Omidi, Y., Barar, J., Ahmadian S. (2008). Characterization and astrocytic modulation of system L transporters in brain microvasculature endothelial cells. Cell Biochemistry and Function, 381–391.
Berendt, M., Farquhar, R. G., Mandigers P. J. (2015). International veterinary epilepsy task force consensus report on epilepsy definition, classification and terminology in companion animals. BMC Veterinary Research, http://researchonline.rvc.ac.uk/9601/1/9601.pdf.
Karaca M., Frigerio, F., Maechler P. (2011). From pancreatic islets to central nervous system, the importance of glutamate dehydrogenase for the control of energy homeostasis. Neurochem. Int, № 59, 510–517.
Fukunaga, K., Saito, M., Matsuo E. (2009). Long-lasting enhancement of CYP activity after discontinuation of repeated administration of phenobarbital in dogs. Research in Veterinary Science, № 87, 455–457.
Looscher W. W. (2003). Grundlagen zur Behandlung von Epilepsie bei Hund und Katze. Prakt Tierarzt, № 84, 574–586.
Junyent, F., Utrera, J., Romero R. (2009). Prevention of Epilepsy by Taurine Treatments in Mice Experimental Model. Journal of Neuroscience Research, № 87, 1500–1508.
El, I. A., Messing, J., Scalia, J., Trenkner E. (2003). Prevention of epileptic seizures by taurine. Adv Exp Med Biol., № 526, 515–525.
Chen, R. Q., Wang, S. H., Yao W. (2011). Role of Glycine Receptors in Glycine-Induced LTD in Hippocampal CA1 Pyramidal Neurons. Neuropsychopharmacology, № 36, 1948–1958.
Semba J., Patsalos P. N. (1993). Milacemide effects on the temporal interrelationship of amino-acids and monoamine metabolites in rat cerebrospinal-fluid. Eur J Pharmacol, № 230, 321 – 326.
Wrzosek M., Nicpon J. (2012). Electroencephalographic monitoring of seizure treatment in 32 dogs – Preliminary results of prospective study. In 25th Annual symposium of European Society of Veterinary Neurology and European Collage of Veterinary Neurology, http://onlinelibrary.wiley.com/doi/10.1111/jvim.12068/pdf.
Dewey, C. W., Guiliano, R., Boothe D. M. (2004). Zonisamide therapy for refractory idiopathic epilepsy in dogs. J Am Anim Hosp Assoc, № 40, 285–291.
Downloads
Published
Issue
Section
License
Relationship between right holders and users shall be governed by the terms of the license Creative Commons Attribution – non-commercial – Distribution On Same Conditions 4.0 international (CC BY-NC-SA 4.0):https://creativecommons.org/licenses/by-nc-sa/4.0/deed.uk
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
